CM |
Apoptosis assay |
~5 μM |
|
induces Apoptosis |
16601284 |
BON |
Apoptosis assay |
~7.5 μM |
|
induces Apoptosis |
16601284 |
CM |
Function assay |
~5 μM |
|
induces cell cycle arrest |
16601284 |
BON |
Function assay |
~7.5 μM |
|
induces cell cycle arrest |
16601284 |
CM |
Growth inhibitory assay |
~5 μM |
|
IC50=3.3 μM |
16601284 |
BON |
Growth inhibitory assay |
~10 μM |
|
IC50=6.6 μM |
16601284 |
BON |
Kinase assay |
~6 μM |
|
induces dephosphorylation of IGF-1R |
16601284 |
SK-Hep-1 |
Function assay |
~10 μM |
|
Induces cell cycle arrest |
16530734 |
Hep-G2 |
Function assay |
~10 μM |
|
Induces cell cycle arrest |
16530734 |
Huh-7 |
Function assay |
~10 μM |
|
Induces cell cycle arrest |
16530734 |
SK-Hep-1 |
Growth inhibitory assay |
~10 μM |
|
IC50=6.9 μM |
16530734 |
Hep-3B |
Growth inhibitory assay |
~10 μM |
|
IC50=1.9 μM |
16530734 |
Hep-G2 |
Growth inhibitory assay |
~10 μM |
|
IC50=1.8 μM |
16530734 |
Huh-7 |
Growth inhibitory assay |
~10 μM |
|
IC50=1.4 μM |
16530734 |
OVCAR-3 |
Function assay |
~15 μM |
|
Decreases phosphorylation of AKT |
16300820 |
OVCAR-4 |
Apoptosis assay |
~15 μM |
|
induces apoptosis |
16300820 |
OVCAR-3 |
Apoptosis assay |
~15 μM |
|
induces apoptosis |
16300820 |
OVCAR-4 |
Growth inhibitory assay |
~15 μM |
|
inhibits cell proliferation |
16300820 |
OVCAR-3 |
Growth inhibitory assay |
~15 μM |
|
inhibits cell proliferation |
16300820 |
RD/18 |
Growth inhibitory assay |
~7 μM |
|
IC50<4 μM |
15867386 |
CCA |
Growth inhibitory assay |
~7 μM |
|
IC50<2 μM |
15867386 |
RMZ-RC2 |
Growth inhibitory assay |
~7 μM |
|
IC50<0.5 μM |
15867386 |
IOR/RCH |
Growth inhibitory assay |
~7 μM |
|
IC50<0.5 μM |
15867386 |
IOR/NGR |
Growth inhibitory assay |
~7 μM |
|
IC50<0.5 μM |
15867386 |
IOR/CAR |
Growth inhibitory assay |
~7 μM |
|
IC50<1 μM |
15867386 |
IOR/BRZ |
Growth inhibitory assay |
~7 μM |
|
IC50<0.5 μM |
15867386 |
LAP35 |
Growth inhibitory assay |
~7 μM |
|
IC50<0.5 μM |
15867386 |
IOR/OS14 |
Growth inhibitory assay |
~7 μM |
|
IC50<4 μM |
15867386 |
IOR/OS10 |
Growth inhibitory assay |
~7 μM |
|
IC50<5 μM |
15867386 |
IOR/OS9 |
Growth inhibitory assay |
~7 μM |
|
IC50<6 μM |
15867386 |
IOR/OS7 |
Growth inhibitory assay |
~7 μM |
|
IC50<1 μM |
15867386 |
MOS |
Growth inhibitory assay |
~7 μM |
|
IC50<4 μM |
15867386 |
SARG |
Growth inhibitory assay |
~7 μM |
|
IC50<3 μM |
15867386 |
6647 |
Growth inhibitory assay |
~7 μM |
|
IC50<0.5 μM |
15867386 |
SJ-Rh 4 |
Growth inhibitory assay |
~7 μM |
|
IC50<0.5 μM |
15867386 |
SJ-Rh 30 |
Growth inhibitory assay |
~7 μM |
|
IC50<0.5 μM |
15867386 |
RD-ES |
Growth inhibitory assay |
~7 μM |
|
IC50<0.5 μM |
15867386 |
SK-N-MC |
Growth inhibitory assay |
~7 μM |
|
IC50<0.5 μM |
15867386 |
SK-ES-1 |
Growth inhibitory assay |
~7 μM |
|
IC50<0.5 μM |
15867386 |
U-2OS |
Growth inhibitory assay |
~7 μM |
|
IC50<0.5 μM |
15867386 |
Saos-2 |
Growth inhibitory assay |
~7 μM |
|
IC50<3 μM |
15867386 |
TC-71 |
Growth inhibitory assay |
~7 μM |
|
IC50<0.5 μM |
15867386 |
TC-71 |
Growth inhibitory assay |
~1 μM |
|
inhibits insulin-like growth factor-I–mediated growth |
15867386 |
32D-Bcr-Abl |
Kinase assay |
~10 μM |
|
inhibits Bcr-Abl p210 with IC50 of >10 μM |
15050915 |
GIST882 |
Kinase assay |
~10 μM |
|
inhibits c-Kit with IC50 of >5 μM |
15050915 |
A31 |
Kinase assay |
~10 μM |
|
inhibits PDGFR with IC50 of >10 μM |
15050915 |
A431 |
Kinase assay |
~10 μM |
|
inhibits HER1 with IC50 of >10 μM |
15050915 |
A14 |
Kinase assay |
~10 μM |
|
inhibits InsR with IC50 of 2.3 ± 0.163 μM |
15050915 |
NWT-21 |
Kinase assay |
~10 μM |
|
inhibits IGF-IR with IC50 of 0.086 ± 0.028 μM |
15050915 |
HT-29 |
Growth inhibitory assay |
~10 μM |
|
IC50=1.7 μM |
17007015 |
HCT-116 |
Growth inhibitory assay |
~10 μM |
|
IC50=2.5 μM |
17007015 |
primary colorectal cancer cells |
Function assay |
~5 μM |
|
alters the morphology of the remaining cells |
17007015 |
HTLA-230 |
Function assay |
~8 μM |
|
inhibits IGF-II-mediated stimulation of IGF-IR and Akt |
17121898 |
KCNR |
Function assay |
~8 μM |
|
inhibits IGF-II-mediated stimulation of IGF-IR and Akt |
17121898 |
SK-N-BE2c |
Function assay |
~8 μM |
|
inhibits IGF-II-mediated stimulation of IGF-IR and Akt |
17121898 |
SK-N-BE |
Function assay |
~8 μM |
|
inhibits IGF-II-mediated stimulation of IGF-IR and Akt |
17121898 |
LAN-5 |
Function assay |
~8 μM |
|
inhibits IGF-II-mediated stimulation of IGF-IR and Akt |
17121898 |
GI-CA-N |
Function assay |
~8 μM |
|
inhibits IGF-II-mediated stimulation of IGF-IR and Akt |
17121898 |
SH-EP |
Function assay |
~8 μM |
|
inhibits IGF-II-mediated stimulation of IGF-IR and Akt |
17121898 |
SK-N-AS |
Function assay |
~8 μM |
|
inhibits IGF-II-mediated stimulation of IGF-IR and Akt |
17121898 |
RN-GA |
Function assay |
~8 μM |
|
inhibits IGF-II-mediated stimulation of IGF-IR and Akt |
17121898 |
SY-5Y(N) |
Function assay |
~8 μM |
|
inhibits IGF-II-mediated stimulation of IGF-IR and Akt |
17121898 |
GI-CA-N |
Growth inhibitory assay |
~8 μM |
|
IC50= 6.8 μM |
17121898 |
SH-EP |
Growth inhibitory assay |
~8 μM |
|
IC50= 3 μM |
17121898 |
HTLA-230 |
Growth inhibitory assay |
~8 μM |
|
IC50= 0.5 μM |
17121898 |
SK-N-BE2c |
Growth inhibitory assay |
~8 μM |
|
IC50= 1.1 μM |
17121898 |
SK-N-BE2 |
Growth inhibitory assay |
~8 μM |
|
IC50= 3 μM |
17121898 |
SY-5Y (N) |
Growth inhibitory assay |
~8 μM |
|
IC50= 2.4 μM |
17121898 |
LAN-5 |
Growth inhibitory assay |
~8 μM |
|
IC50= 0.4 μM |
17121898 |
KCNR |
Growth inhibitory assay |
~8 μM |
|
IC50= 0.4 μM |
17121898 |
RN-GA |
Growth inhibitory assay |
~8 μM |
|
IC50= 1.3 μM |
17121898 |
SK-N-AS |
Growth inhibitory assay |
~8 μM |
|
induces apoptosis |
17121898 |
KCNR |
Apoptosis assay |
~8 μM |
|
induces apoptosis |
17121898 |
GI-CA-N |
Apoptosis assay |
~8 μM |
|
induces apoptosis |
17121898 |
HTLA-230 |
Apoptosis assay |
~8 μM |
|
induces apoptosis |
17121898 |
SK-N-BE2c |
Apoptosis assay |
~8 μM |
|
induces apoptosis |
17121898 |
SY-5Y (N) |
Apoptosis assay |
~8 μM |
|
induces apoptosis |
17121898 |
HL60AR |
Function assay |
160 nM |
|
enhances the levels of p27Kip1 |
17361225 |
HL60AR |
Apoptosis assay |
~200 nM |
|
induces apoptosis |
17361225 |
HPAF-II |
Kinase assay |
~1 μM |
|
inhibits IGF-I-mediated signalling |
18445520 |
HPAF-II |
Growth inhibitory assay |
~2 μM |
|
inhibits cell proliferation |
18445520 |
HPAF-II |
Function assay |
~2 μM |
|
inhibits basal and IGF-I-mediated pancreatic cancer cell migration |
18445520 |
TFK-1 |
Growth inhibitory assay |
~250 nM |
|
IC50=0.26 μM |
20066734 |
EGI-1 |
Growth inhibitory assay |
~250 nM |
|
IC50=0.28 μM |
20066734 |
CC-LP-1 |
Growth inhibitory assay |
~250 nM |
|
IC50=0.15 μM |
20066734 |
CC-SW-1 |
Growth inhibitory assay |
~250 nM |
|
IC50=0.54 μM |
20066734 |
Sk-ChA-1 |
Growth inhibitory assay |
~250 nM |
|
IC50=0.2 μM |
20066734 |
Mz-ChA-1 |
Growth inhibitory assay |
~250 nM |
|
IC50=1.39 μM |
20066734 |
Mz-ChA-2 |
Growth inhibitory assay |
~250 nM |
|
IC50=0.73 μM |
20066734 |
ECC-1 |
Kinase assay |
~10 μM |
|
inhibits IGF-IR activation by 98% |
21295335 |
Ishikawa |
Kinase assay |
~10 μM |
|
inhibits IGF-IR activation by 93% |
21295335 |
USPC-1 |
Kinase assay |
~10 μM |
|
inhibits IGF-IR activation by 100% |
21295335 |
USPC-2 |
Kinase assay |
~10 μM |
|
inhibits IGF-IR activation by 96% |
21295335 |
ECC-1 |
Growth inhibitory assay |
~10 μM |
|
decreases cell proliferation |
21295335 |
Ishikawa |
Growth inhibitory assay |
~10 μM |
|
decreases cell proliferation |
21295335 |
USPC-1 |
Growth inhibitory assay |
~10 μM |
|
decreases cell proliferation |
21295335 |
USPC-2 |
Growth inhibitory assay |
~10 μM |
|
decreases cell proliferation |
21295335 |
HEK293 |
Function assay |
|
60 mins |
Inhibition of full length IGF-1 receptor (unknown origin) autophosphorylation transfected in HEK293 cells pretreated for 60 mins followed by IGF-1 stimulation measured after 10 mins by quantitative Western blot analysis, IC50=0.065μM |
26951753 |
HEK293 |
Function assay |
|
60 mins |
Inhibition of full length insulin receptor (unknown origin) autophosphorylation transfected in HEK293 cells pretreated for 60 mins followed by IGF-1 stimulation measured after 10 mins by quantitative Western blot analysis, IC50=0.892μM |
26951753 |
NWT-21 |
Growth inhibitory assay |
|
|
IC50=0.163 μM |
15050915 |
MCF-7 |
Cytoxicity assay |
|
|
IC50=1.64 μM |
15050915 |
Ba/F3 |
Function assay |
|
|
Inhibition of full length IGF-1 receptor (unknown origin) transfected in Ba/F3 cells assessed as cell proliferation, IC50=0.02μM |
26951753 |
HEK293 |
Function assay |
|
|
Displacement of [3H]-dofetilide from human ERG channel expressed in HEK293 cells, IC50=0.13μM |
26951753 |
Ba/F3 |
Function assay |
|
|
Inhibition of full length insulin receptor (unknown origin) transfected in Ba/F3 cells assessed as cell proliferation, IC50=0.244μM |
26951753 |
TC32 |
qHTS assay |
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells |
29435139 |
NB-EBc1 |
qHTS assay |
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells |
29435139 |
Saos-2 |
qHTS assay |
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells |
29435139 |
LAN-5 |
qHTS assay |
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells |
29435139 |
OHS-50 |
qHTS assay |
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells |
29435139 |
RD |
qHTS assay |
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells |
29435139 |
Rh41 |
qHTS assay |
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells |
29435139 |